Țară: Canada
Limbă: engleză
Sursă: Health Canada
TIAPROFENIC ACID
TEVA CANADA LIMITED
M01AE11
TIAPROFENIC ACID
200MG
TABLET
TIAPROFENIC ACID 200MG
ORAL
100/500/1000
Prescription
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0115902001; AHFS:
APPROVED
2011-05-06
_TEVA-TIAPROFENIC ACID (Tiaprofenic acid) _ _Page 1 of 39_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TEVA–TIAPROFENIC ACID Tiaprofenic Acid Tablets Tablets, 200 mg and 300 mg, for oral use Teva Standard Non-Steroidal Anti-Inflammatory Drug (NSAID) Teva Canada Limited Date of Initial Authorization: 30 Novopharm Court December 31, 1996 Toronto, ON M1B 2K9 Date of Revision: Canada August 15, 2022 www.tevacanada.com Submission Control No.: 261587 _TEVA-TIAPROFENIC ACID (Tiaprofenic acid) _ _Page 2 of 39_ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 08/2022 3 SERIOUS WARNINGS AND PRECAUTIONS BOX 08/2022 7 WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests, _Pregnancy_ 08/2022 7 WARNINGS AND PRECAUTIONS, Skin, _Serious skin reactions_ 08/2022 7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women 08/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES .............................................................................................. 2 TABLE OF CONTENTS ................................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION........................................................................ 4 1 INDICATIONS ..................................................................................................................... 4 1.1 PEDIATRICS ................................................................................................................ 4 1.2 GERIATRICS ................................................................................................................ 4 2 CONTRAINDICATIONS........................................................................................................ 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ................................................................... 5 4 DOSAGE AND ADMINISTRATION .......................................................................... Citiți documentul complet